ArticleEuropean journal of nuclear medicine and molecular imaging2015
[(89)Zr]oxinate4 for long-term in vivo cell tracking by positron emission tomography.
Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- First-in-human dosimetry and biodistribution of [European journal of nuclear medicine and molecular imaging · 2026Article
- Biocompatible Glycoconjugation Enables Sensitive In Vivo Cell Tracking by PET/CT.Journal of medicinal chemistry · 2026Article
- Metabolic Glycoengineering Enables Fluorine-18 Radiolabeling of T Lymphocytes via Dual-Bioorthogonal Chemistry.Bioconjugate chemistry · 2026Article
- Tracking macrophages by direct and indirectEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Biodistribution and persistence of human umbilical cord-derived mesenchymal stem cells in NCG mice: a comparative study.Future science OA · 2025Article
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Pharmaceutics · 2025Review
- Homotypic Targeting of [Pharmaceutics · 2025Article
- Zirconium-89-Oxine Cell Tracking by PET Reveals Preferential Monocyte Recruitment to Cancer and Inflammation over Macrophages.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Intracellular Protein Binding of Zr-89 Oxine Cell Labeling for PET Cell Tracking Studies.Pharmaceutics · 2025Article
- Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.Current radiopharmaceuticals · 2025Review
- In Vivo PET Imaging ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Repurposing iron chelators for accurate positron emission tomography imaging tracking of radiometal-labeled cell transplants.MedComm · 2024Article
- Article
- Biodistribution of Mesenchymal Stromal Cells Labeled with [Molecules (Basel, Switzerland) · 2023Article
- Implant Imaging: Perspectives of Nuclear Imaging in Implant, Biomaterial, and Stem Cell Research.Bioengineering (Basel, Switzerland) · 2023Review
- Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) withMolecules (Basel, Switzerland) · 2023Article
- Labeling T Cells to Track Immune Response to Immunotherapy in Glioblastoma.Tomography (Ann Arbor, Mich.) · 2023Review
- An indium-111-labelled membrane-targeted peptide for cell tracking with radionuclide imaging.RSC chemical biology · 2023Article
- Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.Frontiers in medicine · 2023Review
- Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.European journal of nuclear medicine and molecular imaging · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purpose(111)In (typically as [(111)In]oxinate3) is a gold standard radiolabel for cell tracking in humans by scintigraphy. A long half-life positron-emitting radiolabel to serve the same purpose using positron emission tomography (PET) has long been sought. We aimed to develop an (89)Zr PET tracer for cell labelling and compare it with [(111)In]oxinate3 single photon emission computed tomography (SPECT).
methods[(89)Zr]Oxinate4 was synthesised and its uptake and efflux were measured in vitro in three cell lines and in human leukocytes. The in vivo biodistribution of eGFP-5T33 murine myeloma cells labelled using [(89)Zr]oxinate4 or [(111)In]oxinate3 was monitored for up to 14 days. (89)Zr retention by living radiolabelled eGFP-positive cells in vivo was monitored by FACS sorting of liver, spleen and bone marrow cells followed by gamma counting.
resultsZr labelling was effective in all cell types with yields comparable with (111)In labelling. Retention of (89)Zr in cells in vitro after 24 h was significantly better (range 71 to >90%) than (111)In (43-52%). eGFP-5T33 cells in vivo showed the same early biodistribution whether labelled with (111)In or (89)Zr (initial pulmonary accumulation followed by migration to liver, spleen and bone marrow), but later translocation of radioactivity to kidneys was much greater for (111)In. In liver, spleen and bone marrow at least 92% of (89)Zr remained associated with eGFP-positive cells after 7 days in vivo.
conclusion[(89)Zr]Oxinate4 offers a potential solution to the emerging need for a long half-life PET tracer for cell tracking in vivo and deserves further evaluation of its effects on survival and behaviour of different cell types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.